Aptose to be acquired by Hanmi Pharmaceutical at C$2.41/share, 28% premium to 30-day VWAP

Aptose Biosciences Inc.

Hanmi already owns 19.93% and provided >US$30M in debt facilities over 18 months.
Transaction requires approval of 2/3 of votes, plus minority approval; special meeting by Jan 16, 2026.
Formal valuation by Locust Walk: fair market value range of C$1.00 to C$5.23 per share.
Aptose will be delisted from TSX and cease Canadian reporting obligations after closing.
Officers and directors have entered voting support agreements in favor of the arrangement.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.